Prof Dr Thomas Efferth

Professor Dr. Prof. h. c. mult. Thomas Efferth is chair of the Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Mainz, Germany. He is biologist by training (Technical University of Darmstadt, Germany). His doctoral thesis was completed at the German Cancer Research Center (DKFZ), Heidelberg, Germany (1990). Dr. Efferth was awarded the Ludolf-Krehl-Prize of the Southwest German Association for Medicine (1991), the Willmar-Schwabe-Award of the German Society for Medicinal Plant Research (2006), the citizen medal of the City of Heidelberg, Germany (2008), the CESAR Award for Translational Oncology (2011), the SCENTEDdrop Award on medicinal and flagrant herbs (2015), and the Qihuang International Award of the Chinese Association of Chinese Medicine (2017). Since 2018, he is full member of the World Academy of Sciences. He headed a research group for Pharmaceutical Biology at DKFZ (2005-2009) and was adjunct professor (apl.) at the University of Heidelberg (2007-2009). In 2009, he took over the Chair of Pharmaceutical Biology (full professorship) at the Johannes Gutenberg University, Mainz. Furthermore, he is honorary professor at the Northeast Forestry University, Harbin, and at the Zhejiang Chinese Medical University, Hangzhou, China. Moreover, he is visiting professor at the Zhejiang University of Science and Technology, Hangzhou, China and honorary adjunct professor at the Chinese University Hong Kong. Thomas Efferth has published 540 PubMed-listed papers and in peer-reviewed journals in the field of cancer research, pharmacology, and natural products (Hirsch-factor: 73; citation rate: >22,000; acc. Google Scholar) and a textbook on ‘Molecular Pharmacology and Toxicology’ (Springer Publisher; 2006). He holds 7 patents. The scientific results were communicated in over 250 oral presentation and invited lectures and over 180 poster presentations at national and international conferences and meetings. He is editor-in-chief of Phytomedicine as well as co-editor, associate editor and editorial board member of several scientific journals and scientific advisory board member of the German Pharmaceutical Society and several other institutions. Seven of his former lab members promoted to associate or assistant professors. The focus of Dr. Efferth’s research is on tumor pharmacology, network pharmacology, and the development of novel options for treatment and diagnosis of cancer. A major topic is research on chemical entities from natural sources: 1. Network pharmacological and bioinformatic approaches to unravel modes of actions of synthetic and natural compounds with activity against otherwise drug-resistant tumors (basic research) 2. Predictive and prognostic markers for personalized cancer medicine (translational research) For more details see: Selected papers: • Efferth T. Beyond malaria: The inhibition of viruses by artemisinin-type compounds. Biotechnology Advances 2018;36:1730-7 (IF: 10.6) • Efferth T. From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy. Seminars in Cancer Biology 2017;46:65-83 (IF: 9.1) • Efferth T, Paul NW. Threats to human health by great ocean garbage patches. Lancet Planetary Health. 2017;1:e301-e303. • Li PCH, Lam E, Roos WP, Zdienicka MZ, Kaina B, Efferth T. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Research 2008;68:4347-51. (IF: 9.1) • Efferth T, Konkimalla VB, Wang YF, Sauerbrey A, Furchtbar S, Zintl F, Mattern J, Volm M. Prediction of broad spectrum resistance of tumors towards anticancer drugs. Clinical Cancer Research 2008;14:2405-12. (IF: 9.6) • Steinbach D, Gillet JP, Sauerbrey A, Gruhn B, Dawczynski K, Bertholet V, de Longueville F, Zintl F, Remacle J, Efferth T. ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clinical Cancer Research 2006;12:4357-63. (IF: 9.6). • Efferth T, Bachli EB, Schwarzl SM, Goede JS, West C, Smith JC, Beutler E. Glucose-6-phosphate dehydrogenase (G6PD) deficiency-type Zurich: a splice site mutation as an uncommon mechanism producing enzyme deficiency. Blood 2004;104(8):2608. (IF: 13.1).